检索结果-南通市图书馆

Journal of Geriatric Medicine 2021年第2期3卷 17-26页

作者： Patricia de Castro Rodrigues julia Carvalho Galiano Virginia Fernandes moça Trevizani Fania Cristina Santos Discipline of Geriatrics and Gerontology(DIGG) Federal University of São Paulo(UNIFESP)São PauloBrazil Department of Evidence-Based Medicine Brazilian Cochrane CentreFederal University of São Paulo(UNIFESP)Sao PauloBrazil

Introduction:Locomotion is a determinant of intrinsic capacity of older people and can be limited by dysfunction in locomotory organs,characterizing Locomotive Syndrome(LoS).Knowledge on locomotive problems and sarcopenia,and their interface with quality of life,in the oldest old in the literature is ***:To evaluate the correlation between LoS and sarcopenia and their influence on quality of life in oldest ***:A cross-sectional study of an observational,descriptive and analytical epidemiological survey in independent older adults aged 80 and over from São Paulo,Brazil and who participated in the third wave of the LOCOmoV Project,was carried *** data,comorbidities,functioning in activities of daily living,physical functioning,quality of life,and presence of sarcopenia and LoS were *** statistical analyses included the Test-for-Comparing-Two-Proportions,Pearson's Correlation Coefficient,the chi-Square test and Student´s ***:Thirty oldest old with a mean age of 89.1 years were *** prevalence of LoS was high(53.3%)and correlated significantly with chronic pain(p-value 0.024),worse performance on the SPPB and Gait speed(p-valuemong the oldest old studied and negatively impacted their quality of life,regardless of the presence of sarcopenia.

关键词： Older adults Longevity Locomotive syndrome Sarcopenia Functioning Physical tests Quality of life

Hepatic flow is an intraoperative predictor of early allograft dysfunction in whole-graft deceased donor liver transplantation: An observational cohort study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2019年第9期11卷 689-700页

作者： Pablo Lozano Lominchar Maitane Igone Orue-Echebarria Lorena Martín Cristina julia Lisbona María Magdalena Salcedo Luis Olmedilla Hemant Sharma Jose Manuel Asencio JoséAngel López-Baena General Surgery Department Liver Transplant UnitHospital General Universitario Gregorio MaranonMadrid 28007Spain Anesthesiology Department Liver Transplant UnitHospital General Universitario Gregorio MaranonMadrid 28007Spain Hepatology Department Liver Transplant UnitHospital General Universitario Gregorio MaranonMadrid 28007Spain Department of Transplant Surgery Oschner Medical CenterNew OrleansLA 70816United States

BACKGROUND Early allograft dysfunction(EAD)after liver transplantation(LT)is an important cause of morbidity and *** ensure adequate graft function,a critical hepatocellular mass is required in addition to an appropriate blood *** hypothesized that intraoperative measurement of portal venous and hepatic arterial flow may serve as a predictor in the diagnosis of *** To study whether hepatic flow is an independent predictor of EAD following *** This is an observational cohort study in a single *** arterial blood flow and portal venous blood flow were measured intraoperatively by transit *** was defined using the Olthoff *** and multivariate analyses were used to determine the intraoperative predictors of *** analysis and prognostic factor analysis were performed using the Kaplan-Meier and Cox regression *** A total of 195 liver transplant procedures were performed between January 2008 and December 2014 in 188 patients.A total of 54(27.7%)patients developed *** median follow-up was 39 *** venous flow,hepatic arterial flow(HAF)and total hepatic arterial flow were associated with EAD in both the univariate and multivariate *** is an independent prognostic factor for 30-d patient *** Intraoperative measurement of blood flow after reperfusion appears to be a predictor of EAD;moreover,HAF should be considered a predictor of 30-d patient mortality.

关键词： Hepatic flow Early allograft dysfunction Liver transplant

T-lymphoblastic lymphoma with cutaneous involvement

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2015年第8期3卷 727-731页

作者： Emmanuelle Ginoux Fanny julia Brigitte Balme Luc Thomas Stéphane Dalle Department of Dermatology Centre Hospitalier Lyon-Sud Hospices Civils de Lyon Université Claude Bernard Lyon 1 Unit of Pathology Centre Hospitalier Lyon-Sud Hospices Civils de Lyon Cancer Research Center of Lyon

To study dermatological manifestation of T-lymphoblastic lymphoma and to help clinicians in the diagnosis, we report here the case of a 75-year-old patient who presented with violaceous nodules acquired during the last 4 wk and affecting the scalp and right arm. The diagnosis of systemic lymphoma was suggested upon the appearance of cutaneous tumors, palpable lymph nodes and general symptoms including asthenia and weight-loss. The pathology features: positive immunostaining for CD3 and terminal deoxynucleotidyl transferase(Td T) and staging, led us to the final diagnosis of T-lymphoblastic lymphoma(T-LBL) with cutaneous involvement. He received a CHOP regimen as first-line treatment. Unfortunately, the patient relapsed and died 8 mo after the treatment initiation. T-LBL may be diagnosed by skin lesions. Additional immunostaining including Td T and experienced histopathologists are needed to correctly classify this aggressive disease and discuss the correct management including bone-marrow transplantation where appropriate.

关键词： Cutaneous lymphoma Lymphoblastic lymphoma Skin

Inter- and intraobserver agreement in computed tomography enterography in inflammatory bowel disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第45期22卷 10002-10008页

作者： Natally Horvat Camila Carlos Tavares Adriana Ribas Andrade julia Campos Sim?es Cabral Hilton Muniz Le?o Filho Angela Hissae motoyama Caiado Serli Kiyomi Nakao Ueda André Zonetti de Arruda Leite Aytan Miranda Sipahi Manoel de Souza Rocha Radiology Department Hospital das Clínicas da Faculdade de Medicina da Universidade de S?o Paulo Gastroenterology Department Lim 07 Hospital da Clínicas da Faculdade de Medicina da Universidade de S?o Paulo

AIM To evaluate intra- and interobserver agreement in imaging features in inflammatory bowel disease and comparison with fecal calprotectin(FC) *** Our institutional computed tomography enterography(CTE) database was retrospectively queried to identify patients who underwent CTE from January 2014 to June 2015. Patient inclusion criteria were confirmed inflammatory bowel disease(IBD) and FC collected mo after CTE without any change in clinical treatment or surgical treatment during this interval. The exclusion criterion was poor image quality. Two blinded abdominal radiologists, with 12 and 3 years of experience analyzed the CTE regarding localization(small bowel, colonic, both, or no disease detected);type of IBD(inflammatory, stenosing, fistulizing, > 1 pattern, or normal); and signs of active disease(present or absent). In 42 of 44 patients evaluated, routine CTE reports were made by one of the readers who reevaluated the CTEs ≥ 6 mo later, to determine the intraobserver agreement. FC was considered a sign of disease activity when it was higher than 250 μg/*** Forty-four patients with IBD(38 with Crohn's disease and 6 with ulcerative colitis) were included. There was a moderate interobserver agreement regarding localization of IBD(k = 0.540), type of disease(k = 0.410) and the presence of active signs in CTE(k = 0.419). There was almost perfect intraobserver agreement regarding localization, type and signs of active disease in IBD. The k values were 0.902, 0.937 and 0.830, respectively. After a consensus between both radiologists regarding inflammatory activity in CTE, we found that 24(85.7%) of 28 patients who were classified with active disease had elevated FC, and six(37.5%) of 16 patients without inflammatory activity in CTE had elevated FC(P = 0.003). The correlation between elevated FC and the presence of active disease in CTE was significant(k = 0.495, P = 0.001).CONCLUSION We found almost perfect intraobserver and moderate interobserve

关键词： Crohn’s disease Ulcerative colitis Computed tomography Fecal calprotectin Inflammatory bowel disease activity

Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Hepatology 2012年第12期4卷 382-388页

作者： Víctor Vargas Helena Allende Albert Lecube Maria Teresa Salcedo Juan A Baena-Fustegueras José M Fort Joaquín Rivero Roser Ferrer Roberto Catalán Eva Pardina Santiago Ramón y Cajal Jaime Guardia julia Peinado-Onsurbe Liver Unit Department of MedicineHospital Vall d’HebronUniversitat Autònoma08028 BarcelonaSpain CIBER de Enfermedades Hepáticas y Digestivas Instituto de Salud Carlos Ⅲ28029 MadridSpain Department of Pathology Hospital Vall d’HebronUniversitat Autònoma08035 BarcelonaSpain Endocrinology Service Hospital Vall d’HebronUniversitat Autònoma08035 BarcelonaSpain Diabetes Research Unit CIBER de Diabetes y Enfermedades Metabólicas AsociadasInstituto de Salud Carlos Ⅲ28029 MadridSpain Department of Surgery Hospital Arnau de VilanovaLleida25198 BarcelonaSpain Department of Surgery Mútua de Terrassa08221 BarcelonaSpain Biochemistry and Hormones Hospital Vall d’HebronUniversitat Autònoma08035 BarcelonaSpain Biochemistry and molecular Biology Department Biology FacultyBarcelona University08028 BarcelonaSpain

AIM: To evaluate the effects of surgical weight loss (Roux-en-Y gastric bypass with a modified Fobi-Capella technique) on non alcoholic fatty liver disease in obese patients.

关键词： Non alcoholic fatty liver disease Bariatric surgery Obesity Non alcoholic steatohepatitis

julia和R软件在多介质动力学模型建模中的比较

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

化工环保 2021年第4期41卷 494-499页

作者：莫俊超吴孝槐舒耀皋上海化工研究院有限公司检测中心上海200062 上海化学品公共安全工程技术研究中心上海200062 中国合格评定国家认可委员会北京100062

多介质动力学模型在环境风险评估中正得到越来越多的研究和应用。为了选择合适的建模软件,通过构建不同复杂程度的EQC(平衡判据)动力学模型,使用开源软件julia和R编写模型求解程序,对算法选择、计算效率、模型分析工具和便捷性进行比较... 详细信息

多介质动力学模型在环境风险评估中正得到越来越多的研究和应用。为了选择合适的建模软件,通过构建不同复杂程度的EQC(平衡判据)动力学模型,使用开源软件julia和R编写模型求解程序,对算法选择、计算效率、模型分析工具和便捷性进行比较。结果表明,在多介质动力学模型计算中,julia的计算效率是R的至少10倍,且提供了丰富的算法和模型分析工具,对于复杂模型,建议使用julia计算;但由于目前julia应用的便捷性不如R,对于简单模型,建议使用R计算。化学物质性质不影响模型的运行时间。lsoda是julia中求解多介质动力学模型的首选算法,而lsoda和bdf是R中的首选算法。

关键词：多介质模型动力学 julia软件 R软件开源软件常微分方程

Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2021年第23期27卷 3396-3412页

作者： Ligia Yukie Sassaki Sender J Miszputen Roberto Luiz Kaiser Junior Wilson R Catapani Mauro Bafutto António S Scotton Cyrla Zaltman Julio Pinheiro Baima Hagata S Ramos Mikaell Alexandre Gouvea Faria Carolina D Gonçalves Isabella Miranda Guimaraes Cristina Flores Heda M B S Amarante Rodrigo Bremer Nones JoséMiguel Luz Parente Murilo moura Lima Júlio Maria Chebli Maria de Lourdes Abreu Ferrari julia F Campos Maria G P Sanna Odery Ramos Rogério Serafim Parra Jose J R da Rocha Omar Feres Marley R Feitosa Rosana Fusaro Caratin juliana Tosta Senra Genoile Oliveira Santana Department of Internal Medicine Botucatu Medical School at Sao Paulo State University(UNESP)Botucatu 18618-687São PauloBrazil Department of Gastroenterology Escola Paulista de MedicinaSao PauloSão Paulo 18618-687São PauloBrazil Department of Proctology Kaiser Day HospitalSão Jose do Rio Preto 15015-110São PauloBrazil Department of Gastroenterology Faculdade de Medicina do ABCSanto Andre 09060-870São PauloBrazil Department of Gastroenterology Faculdade de MedicinaGoiania 74535-170GoiásBrazil Department of Gastroenterology CMIP Centro Mineiro de PesquisaJuiz de Fora 36010-570Minas GeraisBrazil Department of Internal Medicine Federal University of Rio de JaneiroRio de Janeiro 21941-913Rio de JaneiroBrazil Department of Gastroenterology Escola Paulista de MedicinaSão Paulo 04023-900São PauloBrazil Hospital de Clínicas de Porto Alegre Hospital de Clínicas de Porto AlegrePorto Alegre 90035-903Rio Grande do SulBrazil Hospital de Clinicas da Universidade Federal do Paraná Hospital de Clinicas da Universidade Federal do ParanáCuritiba ParanáParanáBrazil Gastroenterology Department Hospital Nossa Senhora das GraçasCuritiba 80810-040ParanáBrazil Department of General Medicine Universidade Federal do PiauíTeresina 64049-550PiauíBrazil Gastroenterology Hospital Universitario da Universidade Federal do PiauiTeresina 64049-550PiauíBrazil Department of Medicine University Hospital of Federal University of Juiz de ForaJuiz de ForaJuiz de Fora 36036-247Minas GeraisBrazil Department of Clinical Medicine Universidade Federal de Minas GeraisBelo Horizonte 30130-100Minas GeraisBrazil Hospital de Clinicas da Universidade Federal do Paraná Hospital de Clinicas da Universidade Federal do ParanáCuritiba 80060-900ParanáBrazil Department of Surgery and Anatomy Ribeirao Preto Medical SchoolUniversity of Sao PauloRibeirão Preto 14048-900São PauloBrazil Scientific Affairs Takeda Pharmaceuticals BrazilSao Paulo 04709-011Brazil Clinical Research Takeda PharmaceuticalsSão Paulo 04709-011Sã

BACKGROUND Crohn’s disease(CD)and ulcerative colitis(UC)are inflammatory bowel diseases(IBDs)with a remission-relapsing presentation and symptomatic exacerbations that have detrimental impacts on patient quality of life and are associated with a high cost burden,especially in patients with moderate-to-severe *** Real-world Data of moderate-to-Severe Inflammatory Bowel Disease in Brazil(RISE BR)study was a noninterventional study designed to evaluate disease control,treatment patterns,disease burden and health-related quality of life in patients with moderate-to-severe active *** report findings from the prospective follow-up phase of the RISE BR study in patients with active UC or *** To describe the 12-mo disease evolution and treatment patterns among patients with active moderate-to-severe IBD in *** This was a prospective,noninterventional study of adult patients with active Crohn’s disease(CD:Harvey-Bradshaw Index≥8,CD Activity Index≥220),inadequate CD control(i.e.,calprotectin>200μg/g or colonoscopy previous results),or active ulcerative colitis(UC:Partial Mayo score≥5).Enrollment occurred in 14 centers from October 2016 to February *** proportion of active IBD patients after 9-12 mo of follow-up,Kaplan-Meier estimates of the time to mild or no activity and a summary of treatment initiation,discontinuation and dose changes were *** The study included 118 CD and 36 UC patients,with mean±SD ages of 43.3±12.6 and 44.9±16.5 years,*** most frequent drug classes at index were biologics for CD(62.7%)and 5-aminosalicylate derivates for UC patients(91.7%).During follow-up,65.3%of CD and 86.1%of UC patients initiated a new treatment at least ***/dose changes occurred in 68.1%of CD patients[median 2.0(IQR:2-5)]and 94.3%of UC patients[median 4.0(IQR:3-7)].On average,CD and UC patients had 4.4±2.6 and 5.0±3.3 outpatient visits,*** median time to first mild or no activity was 319(IQR:239-3

关键词： Crohn’s disease Ulcerative colitis Inflammatory bowel diseases Prospective study

高眼压症治疗研究局部用药可以延缓或预防非洲裔美国人原发性开角型青光眼的发生

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

美国医学会眼科杂志（中文版） 2005年第2期17卷 68-75页

作者： Eve J. Higginbotham Mae O. Gordon julia A. Beiser Michael V. Drake G. Richard Bennett M. Roy Wilson Michael A. Kass 张世杰（译）任泽钦（校） From the Department of Ophthalmology Maryland Center for Eye Care Associates Baltimore the Department of Ophthalmology and Visual Sciences Washington University School of Medicine St Louis Mo the University of California San Francisco Oakland Pennsylvania CoLlege of Optometry Philadelphia and Texas Tech University Health Sciences Center Lubbock 不详

背景：非洲裔美国人青光眼的患病率高于白种人。目的：报道高眼压症治疗研究中局部降眼压药延缓或预防非洲裔美国人原发性开角型青光眼（PO-AG）发生的安全性和有效性。方法：入选标准包括年龄在40-80；1只眼眼压在24—32mmHg（1kP=7．5... 详细信息

背景：非洲裔美国人青光眼的患病率高于白种人。目的：报道高眼压症治疗研究中局部降眼压药延缓或预防非洲裔美国人原发性开角型青光眼（PO-AG）发生的安全性和有效性。方法：入选标准包括年龄在40-80；1只眼眼压在24—32mmHg（1kP=7．5mm Hg），另一只眼在21-32mm Hg之间：经过标准的临床检查排除明显的青光眼性结构和功能损害。参加者随机分为观察组和用药组。1636例随机化参加者中，408例自称是非洲裔美国人。主要测量指标：主要指标是发生由POAG引起的可重复性视野异常和（或）可重复性视盘恶化。结果：在非洲裔美国人参加者中。用药组203例中17例（8．4％）在研究期间（平均随访时间78个月）发生了POAG。而观察组205例中33例（16．1％）发生POAG（危险比0．50。95％可信区间0．28—0．90；P=0．02）。结论：局部降眼压的治疗对于延缓或预防非洲裔美国人高眼压症患者POAG的发生是有效的。

关键词：原发性开角型青光眼非洲裔美国人高眼压症局部用药治疗预防延缓局部降眼压药 POAG 可重复性

What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Nephrology 2016年第5期5卷 471-481页

作者： Pablo molina JoséL Górriz Mariola D molina Sandra Beltrán Belén Vizcaíno Verónica Escudero julia Kanter Ana Iávila Jordi Bover Elvira Fernández Javier Nieto Secundino Cigarrán Enrique Gruss Gema Fernández-Juárez Alberto Martínez-Castelao Juan F Navarro-González Ramón Romero Luis M Pallardó Department of Nephrology Dr Peset University Hospital46017 ValenciaSpain Department of Medicine Universitat de València46005 ValenciaSpain Department of Mathematics Universidad de AlicanteSan Vicente del Raspeig03690 AlicanteSpain Department of Nephrology FundacióPuigvert080348 BarcelonaSpain Department of Nephrology Hospital Uni-versitari de LleidaIRBlleida(Institut de Reserca Biomèdica de Lleida)25198 LleidaSpain Department of Nephrology Hospital General Universitario de Ciudad Real13005 Ciudad RealSpain Department of Nephrology Hospital da Costa Burela7880 LugoSpain Department of Nephrology Hospital Universitario Fundación Alcorcón28922 MadridSpain Department of Nephrology Hospital Universitario de BeellvitgeIDIBELLL'Hospitalet de Llobregat08907 BarcelonaSpain Research Unit and Department of Nephrology University Hospital Nuestra Senora de Candelaria38010 Santa Cruz de TenerifeSpain Department of Medicine Universitat Autònoma de Barcelona08193 BarcelonaSpain

AIM To evaluate thresholds for serum 25(OH)D concentrations in relation to death, kidney progression and hospitalization in non-dialysis chronic kidney disease(CKD) *** Four hundred and seventy non-dialysis 3-5 stage CKD patients participating in OSERCE-2 study, a prospective, multicenter, cohort study, were prospectively evaluated and categorized into 3 groups according to 25(OH)D levels at enrollment(less than 20 ng/mL, between 20 and 29 ng/mL, and at or above 30 ng/mL), considering 25(OH)D between 20 and 29 ng/mL as reference group. Association between 25(OH)D levels and death(primary outcome), and time to first hospitalization and renal progression(secondary outcomes) over a 3-year followup, were assessed by Kaplan-Meier survival curves and Cox-proportional hazard models. To identify 25(OH)D levels at highest risk for outcomes, receiver operating characteristic(ROC) curves were *** Over 29 ± 12 mo of follow-up, 46(10%) patients dead, 156(33%) showed kidney progression, and 126(27%) were hospitalized. After multivariate adjustment, 25(OH)D mortality(HR = 2.33; 95%CI: 1.10-4.91; P = 0.027) and kidney progression(HR = 2.46; 95%CI: 1.63-3.71; P model, but not after multivariate adjusting. ROC curves identified 25(OH)D levels at highest risk for death, kidney progression, and hospitalization, at 17.4 ng/mL [area under the curve(AUC) = 0.60; 95%CI: 0.685-0.69; P = 0.027], 18.6 ng/mL(AUC = 0.65; 95%CI: 0.60-0.71; P < 0.001), and 19.0 ng/m L(AUC = 0.56; 95%CI: 0.50-0.62; P = 0.048), ***25(OH)D < 20 ng/mL was an independent predictor of death and progression in patients with stage 3-5 CKD, with no addit

关键词： Vitamin D Chronic kidney disease mortality Renal progression Hospitalization